, Volume 26, Issue 8, pp 1344-1345
Date: 25 Jul 2006

Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Visceral leishmaniasis (VL) is a severe disease that can develop in immunocompromised patients. Antitumor necrosis factor-α (TNF-α) treatment of rheumatoid arthritis can result in clinical benefits, but with an increased risk of opportunistic infections. Leishmania infection in patients treated with TNF-α antagonists is extremely rare; for this reason, we report a patient with VL after etanercept treatment who had an unfavorable outcome.